DOCSLIB.ORG

(≥4CLR) Flow Cytometry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(≥4CLR) Flow Cytometry European Research Initiative on CLL (ERIC) guidelines for the detection of minimal residual disease in CLL using multi- parameter (≥4CLR) flow cytometry Andy C. Rawstron; Claudia Fazi; Andreas Agathangelidis; Neus Villamor; Remi Letestu; Josep Nomdedeu; Carlos Palacio; Olga Stehlikova; Karl- Anton Kreuzer; Stuart Liptrot; David O’Brien; Ruth M. de Tute; Martin Spacek; Johan Dobber; Arnon P. Kater; Peter Gambell; Asha Soosapilla; Gerard Lozanski; Gabriele Brachtl; Ke Lin, Curtis Hanson; Jeffrey L. Jorgensen; Maryalice Stetler-Stevenson; Constance Yuan; Beth Broome; Fiona Craig; Julio Delgado; Carol Moreno; Francesc Bosch; Alexander Egle; Michael Doubek; Sarka Pospisilova; Stephen Mulligan; David Westerman; Tait Shanafelt; Andy Pettitt; Thomas J. Kipps; William G. Wierda; Florence Cymbalista; Michael Hallek; Peter Hillmen; Emili Montserrat and Paolo Ghia on behalf of the ERIC consortium Lessons from the several years of attempting to harmonise CLL MRD by flow cytometry • The CLL community needs to progress – Flow MRD can easily achieve 10-5, but do we want this if it then means there are insufficient cells left to test the novel assay that can achieve 10-6 ? • The participating labs need flexibility – Variable equipment specification, reagents restricted to certain suppliers, compatibility with local procedures, locally critical markers (CD160, ROR1) • Researchers and biotech need to know that their assay meets requirements without re-validating every individual combination – Provide a specification for the required components so that developers can demonstrate approved standard. Guidelines on the validation of cell-based assays • Sensitivity – Either: “lowest signal detectable above background” – Or: “true positive / true positive + false negative” • Limit of Blank (LOB) = highest signal in the absence of measurand, calculated as mean (blank) + 1.645 SD (95% of negative values are below this limit) • Limit of Detection (LOD) = level at which 95% of samples with low level of measurand are detected above the limit of blank, calculated as LOB + 1.645 SD • Limit of Quantification (LoQ) = lowest level of measurand that can be reliably detected and whose total error (bias + Imprecision) meets a desired criterion for accuracy (clinical utility) Cytometry Part B (Clinical Cytometry) 84B: 315-323 Clinically appropriate level of variation: When BCR-ABL RQ-PCR accepted as a trial end-point, 95% limit of agreement = ± 5-fold CML: best 95% LOA +/- 2-fold using synthetic standards CLL: Target: ±3-fold (0.5log), preferably ±2-fold (0.3 log) Multiparameter flow CLL MRD Guidelines: aims of the project • The primary aim of this project was to identify and validate the specification of an assay that could provide a stable core set of markers for MRD detection: – at the levels required by the IWCLL guidelines or better – compatible with published outcome data – independent of instrument/reagent manufacturer – offer sufficient flexibility for the use and validation of additional markers. • The secondary aim of this study was to compare the assay with High Throughput Sequencing to determine the most appropriate application of each technology. 4 vs. 6 vs. 8-CLR Component markers PerCP PE- APC- FITC PE -Cy5.5 Cy7 APC H7 CD45 CD3 CD19 CD5 CD20 CD38 CD19 CD5 CD81 CD22 CD19 CD5 CD43 CD79b CD19 CD5 CD3 CD38 CD5 CD19 CD79b CD20 CD81 CD22 CD5 CD19 CD43 CD20 4CLR 20-50 CLL events in ≥2 of 3 tubes 6CLR 20-50 CLL events in both tubes PerCP- V450 V500 FITC PE Cy5.5 PE-Cy7 APC APC-H7 CD5 CD3 CD81 CD79b CD22 CD19 CD43 CD20 1-tube 8-CLR dilution analysis 10 1 CLR assay CLR - 0.1 tube 8 tube - 0.01 0.001 0.0001 CLL % leucocytes using 1 using % CLL leucocytes 0.00001 0.00001 0.0001 0.001 0.01 0.1 1 10 Expected CLL % leucocytes A) 8-CLR 1-tube panel dilution analysis PerCP- V450 V500 FITC PE Cy5.5 PE-Cy7 APC APC-H7 CD5 CD3 CD81 CD79b CD22 CD19 CD43 CD20 6-markers are sufficient for MRD detection 10 1 0.8 1 and CLR - 0.6 Below LOD Above LOQ CLR assay CLR - 0.4 0.1 0.2 tube 8 tube - 0.01 0 -0.2 0.001 -0.4 -0.6 0.0001 CLL % leucocytes using 1 using % CLL leucocytes -0.8 core marker single tube assays (log transformed) assays tube single marker core Difference in CLL inDifference of % leucocytes8 between 0.00001 -1 0.00001 0.0001 0.001 0.01 0.1 1 10 0.0001 0.001 0.01 0.1 1 10 100 Expected CLL % leucocytes CLL % of leucocytes average of 8-CLR and core marker single tube assays A) 8-CLR 1-tube panel dilution B) 6 markers are sufficient for analysis detection of MRD PerCP- V450 V500 FITC PE Cy5.5 PE-Cy7 APC APC-H7 CD5 CD3 CD81 CD79b CD22 CD19 CD43 CD20 1-tube 6-CLR analysis limit of detection 10-5 with acceptable inter-operator variation 10 1 core panel core 0.1 - 0.01 0.001 CLL % leucocytes using MRD using % CLL leucocytes 0.0001 0.00001 0.00001 0.0001 0.001 0.01 0.1 1 10 Expected CLL % leucocytes A) 6-CLR 1-tube core marker panel B) Variation tested in 19 students at dilution analysis: LoD 0.001% ESCCA-sponsored educational meetings Figure 3: A platform-independent specification for MRD-flow reagents Acceptable Sub-optimal CLL cells Normal B-cells Normal T-cells A platform-independent specification for MRD-flow reagents Control populations in normal Minimum Typical peripheral blood Expression Relative Antigen fluorescence (% pos vs. intensity ‡ Positive Negative control) (preferred) CD5 Positive (>20%) CD3+ T-cells CD19+ B-cells >30 (>65) CD20 Weak CD19+ B-cells CD3+ T-cells >13 (>20) CD43 Positive (>20%) CD3+ T-cells CD20+ B-cells >15 (>40) CD79b Weak CD20+ B-cells CD3+ T-cells >15 (>30) CD81 Weak CD3+ T-cells Granulocytes >12 (>20) LoD: (≤) 1 in a million Case 1 Case 2 Case 3 Sequence 1 Sequence 2 Average of S1 & S2 Dilutional analysis (Milan) assessing high-throughput sequencing: analysis of 3 CLL cases diluted into leucocytes from leucodpletion filters in serial 1:10. Each CLL clone was tagged with 2 sequences, 1 productive and 1 non-productive. The plot shows the CLL sequence as a percentage of nucleated genomes. For log-transformed data above the LoQ, linearity = 1.15, correlation co-efficient (Pearson R) = 0.980, average difference = 0.15 log, 95% limit of agreement 0.76 log. ClonoSEQ HTS in comparison to Sanger sequencing and MRD-flow in patient samples • Identifying a clonal marker: HTS MRD-core (CLL ClonoSEQ REF cells % of (neoplastic detected a dominant clone (median leucocytes) sequences % of 99.1%, range 7.8-100%) in 66/68 H24O286M <0.001 0.00035 samples vs. 57/68 by Sanger H003O335M <0.001 0.00054 sequencing H235O273M <0.001 0.00061 – 1 technical issue / 1 LC-MBL H78O277M [0.002] 0.0022 H93O275M 0.008 0.0039 • Clonal IGH CDR3 sequences H69O280M 0.012 0.0051 were identical in 49/57 H112O101M <0.001 0.0082 H204O278M 0.46 0.46 – 5 cases Sanger-identified clone H104O351M 23 0.55 detected by HTS (3/5 H104O351M 13 0.55 unproductive, 2/5 not dominant) H67O274M 1.48 0.56 – 3 discrepant in LC-MBL (HTS H64O385M 1.59 0.99 most likely correct) H130O285M 0.3 10.5 • Repeat analysis confirms dominant 12/13 concordant at 0.01% threshold clone in 10/10 CLL/HC-MBL cases (1 flow below LoQ) 3/13 MRD detected by ClonoSEQ not by flow HTS shows greater variation in quantification above 0.01% but better accuracy below 0.01% 4-CLR vs. ≥6-CLR flow cytometry HTS vs. ≥6-CLR flow cytometry Comparison of the MRD-core panel with ClonoSEQ high throughput sequencing: analysis of 3 CLL cases diluted into leucocytes from leucodpletion filters in serial 1:10 dilutions and 13 CLL cases after treatment. The results are not corrected for LoD/LoQ. For log-transformed data above the LoQ, linearity = 0.905, correlation co- efficient (Pearson R) = 0.870, average difference = 0.078 log, 95% limit of agreement 1.5 log. Multiparameter flow CLL MRD guidelines: aims of the project • Identify assay specification for CLL MRD analysis to achieve at least 0.01% limit of quantification – CD19 (or appropriate gating markers) in combination with CD5, CD20, CD43, CD79b, CD81 markers meeting defined specification – Interoperator variation in analysis: 95% LOA within 2-fold (log- scale, ±0.3) achieved by operators after reviewing protocol / test cases. • Compare ≥4CLR MRD flow with high-throughput sequencing – Optimal combination direct quantitative assay to 0.01 - 0.001% (10-4 to 10-5) combined with HTS to exclude disease below 1 in a million (10-6). Different ERIC-harmonised approaches for MRD detecetion B-cell Requires capacity to reflex to full enumeration + Relatively inexpensive and simple. MRD assay if CLL cells <1% clonality &/or B-cells polyclonal. assessment Published outcome data Limit of detection >0.005% 4-colour 4-tube Does not require pre-treatment More material required to phenotype for typical CLL achieve higher detection limits Harmonised with published Intermediate LoD/LoQ outcome data Intermediate amount of 6-colour 2-tube Does not require pre-treatment materialrequired to achieve phenotype for typical CLL higher detection limits. Flexibility for individual laboratory 6-colour core requirements Knowledge of pre-treatment panel for ≥6- LoD 0.001% (10-5), LoQ 0.0025% phenotype preferable. colour assays Allows simultaneous analysis of additional markers LoD 0.0001% (10-6) Further development work on High throughput Objective analysis, does not standardisation of the sequencing necessarily require expert quantification interpretation Acknowledgements Johan Dobber, Arnon Kater Academic Medical Center, Amsterdam, The Netherlands. Remi Letestu, Florence Cymbalista AP-HP, Hôpital Avicenne, Bobigny, France Martin Spacek Charles University in Prague, Czech Republic Neus Villamor, Julio Delgado Hospital Clínic, Barcelona, Spain.
Load more

Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors
    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
    [Show full text]
  • Cd160 Mouse Shrna Plasmid (Locus ID 54215) – TR514223 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TR514223 Cd160 Mouse shRNA Plasmid (Locus ID 54215) Product data: Product Type: shRNA Plasmids Product Name: Cd160 Mouse shRNA Plasmid (Locus ID 54215) Locus ID: 54215 Synonyms: AU045688; By55 Vector: pRS (TR20003) Format: Retroviral plasmids Components: Cd160 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 54215). 5µg purified plasmid DNA per construct Non-effective 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. RefSeq: BC021596, NM_001163496, NM_001163497, NM_018767 Summary: CD160 antigen: Receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3- kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells (By similarity). Receptor for both classical and non-classical MHC class I molecules (PubMed:16177084). Receptor or ligand for TNF superfamily member TNFRSF14, participating in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. Upon ligation of TNFRSF14, provides stimulatory signal to NK cells enhancing IFNG production and anti-tumor immune response (PubMed:25711213). On activated CD4+ T cells, interacts with TNFRSF14 and downregulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (By similarity). In the context of bacterial infection, acts as a ligand for TNFRSF14 on epithelial cells, triggering the production of antimicrobial proteins and proinflammatory cytokines (PubMed:22801499).[UniProtKB/Swiss-Prot Function] shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Tools for Cell Therapy and Immunoregulation
    RnDSy-lu-2945 Tools for Cell Therapy and Immunoregulation Target Cell TIM-4 SLAM/CD150 BTNL8 PD-L2/B7-DC B7-H1/PD-L1 (Human) Unknown PD-1 B7-1/CD80 TIM-1 SLAM/CD150 Receptor TIM Family SLAM Family Butyrophilins B7/CD28 Families T Cell Multiple Co-Signaling Molecules Co-stimulatory Co-inhibitory Ig Superfamily Regulate T Cell Activation Target Cell T Cell Target Cell T Cell B7-1/CD80 B7-H1/PD-L1 T cell activation requires two signals: 1) recognition of the antigenic peptide/ B7-1/CD80 B7-2/CD86 CTLA-4 major histocompatibility complex (MHC) by the T cell receptor (TCR) and 2) CD28 antigen-independent co-stimulation induced by interactions between B7-2/CD86 B7-H1/PD-L1 B7-1/CD80 co-signaling molecules expressed on target cells, such as antigen-presenting PD-L2/B7-DC PD-1 ICOS cells (APCs), and their T cell-expressed receptors. Engagement of the TCR in B7-H2/ICOS L 2Ig B7-H3 (Mouse) the absence of this second co-stimulatory signal typically results in T cell B7-H1/PD-L1 B7/CD28 Families 4Ig B7-H3 (Human) anergy or apoptosis. In addition, T cell activation can be negatively regulated Unknown Receptors by co-inhibitory molecules present on APCs. Therefore, integration of the 2Ig B7-H3 Unknown B7-H4 (Mouse) Receptors signals transduced by co-stimulatory and co-inhibitory molecules following TCR B7-H5 4Ig B7-H3 engagement directs the outcome and magnitude of a T cell response Unknown Ligand (Human) B7-H5 including the enhancement or suppression of T cell proliferation, B7-H7 Unknown Receptor differentiation, and/or cytokine secretion.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Germ-Line Regulation of the Caenorhabditis Elegans Sex-Determining Gene Tra-2
    DEVELOPMENTAL BIOLOGY 204, 251–262 (1998) ARTICLE NO. DB989062 Germ-Line Regulation of the Caenorhabditis elegans Sex-Determining Gene tra-2 Patricia E. Kuwabara,* Peter G. Okkema,† and Judith Kimble‡ *MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, United Kingdom; †Laboratory for Molecular Biology, University of Illinois at Chicago, Chicago, Illinois 60607; and ‡Howard Hughes Medical Institute, Laboratory of Molecular Biology, Department of Biochemistry, and Department of Medical Genetics, University of Wisconsin, Madison, Wisconsin 53706 The Caenorhabditis elegans sex-determining gene tra-2 promotes female development of the XX hermaphrodite soma and germ line. We previously showed that a 4.7-kb tra-2 mRNA, which encodes the membrane protein TRA-2A, provides the primary feminizing activity of the tra-2 locus. This paper focuses on the germ-line activity and regulation of tra-2. First, we characterize a 1.8-kb tra-2 mRNA, which is hermaphrodite-specific and germ-line-dependent. This mRNA encodes TRA-2B, a protein identical to a predicted intracellular domain of TRA-2A. We show that the 1.8-kb mRNA is oocyte-specific, suggesting that it is involved in germ-line or embryonic sex determination. Second, we identify a tra-2 maternal effect on brood size that may be associated with the 1.8-kb mRNA. Third, we investigate seven dominant tra-2(mx) (for mixed character) mutations that sexually transform hermaphrodites to females by eliminating hermaphrodite spermatogenesis. Each of the tra-2(mx) mutants possesses a nonconserved missense change in a 22-amino-acid region common to both TRA-2A and TRA-2B, called the MX region.
    [Show full text]
  • ORIGINAL ARTICLE Flow Cytometric Protein Expression Profiling As a Systematic Approach for Developing Disease-Specific Assays
    Leukemia (2006) 20, 2102–2110 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens AC Rawstron, R de Tute, AS Jack and P Hillmen Haematological Malignancy Diagnostic Service (HMDS), Leeds Teaching Hospitals, Leeds, UK Depletion of disease below the levels detected by sensitive sustained remissions only occur in patients achieving an MRD- minimal residual disease (MRD) assays is associated with negative complete response.12 Therefore MRD is increasingly prolonged survival in chronic lymphocytic leukaemia (CLL). being used as an end point for therapeutic trials, and several Flow cytometric MRD assays are now sufficiently sensitive and rapid to guide the duration of therapy in CLL, but generally rely studies are now using the assessment of MRD to define the on assessment of CD20 expression, which cannot be accurately duration of therapy. measured during and after therapeutic approaches containing Approaches using allele-specific oligonucleotide polymerase rituximab. The aim of this study was to use analytical software chain reaction (ASO-PCR) to the immunoglobulin gene of the developed for microarray analysis to provide a systematic B-CLL cell are generally accepted to show the highest sensitivity approach for MRD flow assay development. Samples from CLL for MRD detection. However, more recent four-colour ap- patients (n ¼ 49), normal controls (n ¼ 21) and other B-lympho- proaches show sensitivities nearing that of ASO-PCR6,11,13 with proliferative disorders (n ¼ 12) were assessed with a panel of 66 antibodies.
    [Show full text]
  • ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway † Qian Zhang,* Hong Y
    Published September 18, 2019, doi:10.4049/jimmunol.1801327 Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway † Qian Zhang,* Hong Y. Wang,* Xiaobin Liu,* Selene Nunez-Cruz,* Mowafaqx Jillab, Olga Melnikov,† Kavindra Nath,‡ Jerry Glickson,‡ and Mariusz A. Wasik*,†, Inhibitors of Bruton tyrosine kinase (BTK), a kinase these mechanisms is of uttermost importance in design- downstream of BCR, display remarkable activity in a ing an appropriate therapeutic strategy to counteract the subset of mantle cell lymphoma (MCL) patients, but reprogramming. the drug resistance remains a considerable challenge. In ROR1 belongs to the receptor tyrosine kinase-like orphan this study, we demonstrate that aberrant expression of receptor (ROR) family and displays very restricted expression ROR1 (receptor tyrosine kinase-like orphan receptor 1), in normal tissues (11, 12). ROR1 is aberrantly expressed in seen in a large subset of MCL, results in BCR/BTK– various malignancies, including small lymphocytic lymphoma/ independent signaling and growth of MCL cells. ROR1 chronic lymphocytic leukemia (SLL/CLL) and MCL. ROR1 forms a functional complex with CD19 to persistently activates signaling molecules, such as RAC-1 and contractin activate the key cell signaling pathways PI3K–AKT and (13, 14), to promote cell proliferation, survival, and migration MEK–ERK in the BCR/BTK–independent manner. (13–15). CD19 is a B cell–specific receptor capable of stimu- lating the growth of malignant B cells (16). In normal This study demonstrates that ROR1/CD19 complex B lymphocytes, it is activated by SRC family kinases and effectively substitutes for BCR–BTK signaling to SYK, both downstream of BCR (17).
    [Show full text]
  • And Crry, the Two Genetic Homologues of Human CR1 by Hector Molina,* Winnie Wong,~ Taroh Kinoshita,$ Carol Brenner,* Sharon Foley,* and V
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Disfin_ct Receptor and Regulatory Properties of Recombinant Mouse Complement Receptor 1 (CR1) and Crry, the Two Genetic Homologues of Human CR1 By Hector Molina,* Winnie Wong,~ Taroh Kinoshita,$ Carol Brenner,* Sharon Foley,* and V. Michael Holers* From the *Howard Hughes Medical Institute Laboratories and Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri 63110; the *BASF Bioresearch Corporation, Cambridge, Massachusetts 02139; and the SDepartraent of Immunoregulation, Research Institute for Microbial Diseases, Osaka University, Osaka 565, Japan Summary The relationship between the characterized mouse regulators of complement activation (RCA) genes and the 190-kD mouse complement receptor 1 (MCK1), 155-kD mouse complement receptor 2 (MCR2), and mouse p65 is unclear. One mouse RCA gene, designatedMCR2 (or Cr2), encodes alternatively spliced 21 and 15 short consensus repeat (SCR)-containing transcripts that crosshybridize with cDNAs of both human CR2 and CR1, or CR2 alone, respectively. A five SCR-containing transcript derived from a second unique gene, designated Crry, also crosshybridizes with human CR1. We have previously shown that the 155-kD MCR2 is encoded by the 15 SCR-containing transcript. To analyze the protein products of the other transcripts, which are considered the genetic homologues of human CRI, we have expressed the 21 and the 5 SCR-containing cDNAs in the human K562 erythroleukemia cell line. We demonstrate that cells expressing the 21 SCK transcript express the 190-kD MCR1 protein. These cells react with five unique rat anti-MCR1 monodonal antibodies, including the 8C12 antibody considered to be monospecific for MCK1.
    [Show full text]
  • Transcriptional Control of Tissue-Resident Memory T Cell Generation
    Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Filip Cvetkovski All rights reserved ABSTRACT Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Tissue-resident memory T cells (TRM) are a non-circulating subset of memory that are maintained at sites of pathogen entry and mediate optimal protection against reinfection. Lung TRM can be generated in response to respiratory infection or vaccination, however, the molecular pathways involved in CD4+TRM establishment have not been defined. Here, we performed transcriptional profiling of influenza-specific lung CD4+TRM following influenza infection to identify pathways implicated in CD4+TRM generation and homeostasis. Lung CD4+TRM displayed a unique transcriptional profile distinct from spleen memory, including up-regulation of a gene network induced by the transcription factor IRF4, a known regulator of effector T cell differentiation. In addition, the gene expression profile of lung CD4+TRM was enriched in gene sets previously described in tissue-resident regulatory T cells. Up-regulation of immunomodulatory molecules such as CTLA-4, PD-1, and ICOS, suggested a potential regulatory role for CD4+TRM in tissues. Using loss-of-function genetic experiments in mice, we demonstrate that IRF4 is required for the generation of lung-localized pathogen-specific effector CD4+T cells during acute influenza infection. Influenza-specific IRF4−/− T cells failed to fully express CD44, and maintained high levels of CD62L compared to wild type, suggesting a defect in complete differentiation into lung-tropic effector T cells.
    [Show full text]
  • Cd79a Percp-Cy5.5 Noto Anche Come: Mb-1 Catalog Number(S): 9045-0792-025 (25 Tests), 9045-0792-120 (120 Tests)
    Page 1 of 2 CD79a PerCP-Cy5.5 Noto anche come: mb-1 Catalog Number(s): 9045-0792-025 (25 tests), 9045-0792-120 (120 tests) Profili di fluorescenza di normali linfociti del sangue periferico umano non colorati (istogramma blu) o colorati a livello intracellulare con CD79a coniugati con PerCP-Cy5.5 (istogramma viola). Informazioni sul prodotto Indice: CD79a PerCP-Cy5.5 Storage Conditions: Conservare a 2-8 °C. Catalog Number(s): 9045-0792-025 (25 tests), Non congelare. 9045-0792-120 (120 tests) Materiale fotosensibile. Clone: HM47 Attenzione: contiene azide Concentrazione: 5 µl (0,03 µg)/test (un test viene Manufacturer: eBioscience, Inc., 10255 Science definito come la quantità in grado di colorare Center Drive, San Diego, CA 92121, USA 1x10e6 cellule in 100 μl) Authorized Representative: Bender MedSystems Ospite/isotipo: IgG1 di topo, kappa GmbH, an eBioscience Company Campus Vienna Workshop HLDA: V Biocenter 2 A-1030 Vienna Austria Formulazione: Tampone acquoso, 0,09% di sodio azide; può contenere proteina carrier/stabilizzante. Uso previsto Descrizione L'anticorpo monoclonale HM47 coniugato con fluorocromo L'anticorpo monoclonale HM47 riconosce il dominio reagisce con l'antigene CD79a umano. Il CD79a può essere citoplasmatico del CD79a, chiamato anche mb-1. Il CD79a è rilevato in campioni biologici umani mediante tecniche una glicoproteina di membrana da 47 kDa che si unisce al immunologiche. CD79b con cui forma il recettore eterodimerico per i linfociti Principi del test B (BCR). Questo recettore è responsabile della segnalazione La citometria a flusso è uno strumento utile per la misurazione dei linfociti B e causa la loro attivazione, apoptosi o anergia.
    [Show full text]
  • Research Article Microarray Analysis of the Molecular Mechanism Involved in Parkinson’S Disease
    Hindawi Parkinson’s Disease Volume 2018, Article ID 1590465, 12 pages https://doi.org/10.1155/2018/1590465 Research Article Microarray Analysis of the Molecular Mechanism Involved in Parkinson’s Disease Cheng Tan, Xiaoyang Liu, and Jiajun Chen Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China Correspondence should be addressed to Jiajun Chen; [email protected] Received 24 May 2017; Revised 21 August 2017; Accepted 18 October 2017; Published 1 March 2018 Academic Editor: Amnon Sintov Copyright © 2018 Cheng Tan et al. )is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Purpose. )is study aimed to investigate the underlying molecular mechanisms of Parkinson’s disease (PD) by bioinformatics. Methods. Using the microarray dataset GSE72267 from the Gene Expression Omnibus database, which included 40 blood samples from PD patients and 19 matched controls, differentially expressed genes (DEGs) were identified after data preprocessing, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Protein-protein interaction (PPI) network, microRNA- (miRNA-) target regulatory network, and transcription factor- (TF-) target regulatory networks were constructed. Results. Of 819 DEGs obtained, 359 were upregulated and 460 were downregulated. Two GO terms, “rRNA processing” and “cytoplasm,” and two KEGG pathways, “metabolic pathways” and “TNF signaling pathway,” played roles in PD development. Intercellular adhesion molecule 1 (ICAM1) was the hub node in the PPI network; hsa- miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b participated in PD pathogenesis.
    [Show full text]